Drug Trial Radar · NCT07731919
Study on Doses of Inhaled ALX1 in Adults With Bronchiectasis
Last checked: Nov 20, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
28
Planned (sponsor's estimate)
Start
Sep 1, 2026
Primary completion
Mar 31, 2027
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- Vast TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jul 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and effects of ALX1, an inhaled investigational treatment, in adults with bronchiectasis. Participants will receive either ALX1 or a placebo (a treatment with no active medicine) for 14 days. The study will compare different dose levels of ALX1 to help identify appropriate doses for future research based on safety, tolerability, and changes in predictive biomarkers.
Conditions
- Bronchiectasis Adult
Interventions
ALX1Drug
Dose Formulation: Solution for inhalation Dose Strength: 28 mg/mL Route of Administration: Inhalation via nebulizer
PlaceboDrug
Dose Formulation: Solution for inhalation Dose Strength: 0.9% sodium chloride Route of Administration: Inhalation via nebulizer
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with a metHb value ≥ 5% per dose levelTime frame: From Day 1 to Day 14 (EOT visit)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.